ECI830

· Novartis Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ECI830, covering 2026-04-17 to 2026-04-17. Get the full timeline:

Most recent: Clinical Trial Update: Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors [Phase 1, Phase 2]

See pricing